Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes

Vascular health and risk management

Volumn 10, Issue , 2014, Pages 661-664

  Blüher, Matthias ^a   Schweizer, Anja ^a   Bader, Giovanni ^a   Foley, James E ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

dipeptidyl peptidase 4 inhibitor; glucagon like peptide 1; hyperglycemia; renal threshold; sodium glucose cotransporter 2 inhibitor

Indexed keywords

ADAMANTANE; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; NITRILE; PYRROLIDINE DERIVATIVE; VILDAGLIPTIN;

ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD; BODY WEIGHT; CALORIC INTAKE; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; META ANALYSIS; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; TIME; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

ADAMANTANE; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENERGY INTAKE; FASTING; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NITRILES; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT LOSS;

EID: 84927172239     PISSN: None     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S73608     Document Type: Article

References (0)